Erste Group analysts upgraded Eli Lilly stock from Hold to Buy, citing a robust product demand and a promising pipeline of potential successes. The analysts highlighted the pharmaceutical company's ...

The Washington University trial comes as part of a larger platform study which hopes to understand if Alzheimer's disease can ...

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

Request To Download Free Sample of This Strategic Report @ Highlighted with 43 tables and 86 figures, this 160-page report ?Europe Biopharmaceuticals Market 2023-2033 by Product Type, Testing Service ...

Peptide Therapeutics MarketThe global peptide therapeutics market is set for remarkable expansion, with its valuation projected to grow from USD 42.1 billion in 2024 to USD 117.4 billion by 2034. The ...

As we move forward, the BMC remains dedicated to its mission of elevating industry-wide excellence in biospecimen management, raising the bar for data integrity and quality, enabling the future of ...

A global pharmaceutical company partnered with DelveInsight to create a robust and simplified solution enabling its top executives to monitor the evolving breast cancer competitive intelligence ...

HR+/HER2- breast cancer is the most prevalent subtype of breast cancer, defined by cancer cells that possess hormone ...

Experts believe that pharma will continue as normal due to the scientific justification of running diverse clinical trials.

Eli Lilly & Co. (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. Its products span oncology, ...

The top 20 biopharmaceutical companies experienced mixed performance in 2024 amid a dynamic landscape influenced by various ...

Chronic Pain, that persists beyond the usual recovery period or occurs along with a chronic <a target=_blank href= ...